In order to evaluate the specificity of alkyl-lysophospholipid-induced cell destruction, peripheral blood leukocytes from chronic myelogenous leukemia (CML) patients in chronic phase of the disease as well as in blastic crisis have been separated by density centrifugation. These subpopulations, enriched for the different maturation stages, were tested for their sensitivity to alkyl-lysophosphol...

The predominant circulating cells in chronic myelogenous leukemia (CML) morphologically resemble normal myeloid precursors; however, certain characteristics indicate the two are not identical. Approximately 88% of the patients with clinically typical CML present with a cytogenetic abnormality known as the Philadelphia chromosome (Ph1). Additionally, the leukocyte alkaline phosphatase (LAP) valu...

Chronic myelogenous leukemia (CML) stem cells are the cellular source of vast majority mature CML and responsible for relapse disease post-tyrosine kinase inhibitor (TKI) therapy. Although cells, whose active division is driven by BCR-ABL1 oncogene-dependent signaling, reduced TKI therapy, resistant because they become quiescent via a heretofore elusive mechanism that independent oncogene signa...

Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML). A standard risk group of 20 patients included those with acute leukemia in remission and CML in chronic phase. A high-risk group of 30 patien...

Polycythemia vera is a prototype and also the most common of the four classical myeloproliferative disorders—chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Our understanding of the last three disorders has lagged behind in comparison to our understanding of the molecular basis of CML, which led to the development of t...

Haematologica/journal of hematology vol. 88(02):February 2003 229 ics of STI571 in a phase 1 trial in chronic myelogenous leukemia (CML) patients. Proc Am Assoc Cancer Res 2000;41:3468[abstract]. 4. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7. 5. Marin D, Marktel S, Bua M, Olavarria E,...

Lineage switch is a very rare event in blastic crisis of chronic myelogenous leukemia (CML-BC). To our knowledge, only three cases of lineage switch between lymphoid and myeloid/myelomonocytic lineages have been reported in the literature. Here, we report a novel case of imatinib-resistant CML-BC, in which the blast lineage switched from biphenotypic to B-lymphoid.

Most patients with chronic myelogenous leukemia (CML) show a Philadelphia (Ph) chromosome with a characteristic translocation between chromosomes 9 and 22. However, there are variant complex translocations involving other chromosomes in addition to the standard translocation. We describe a case of CML showing a complex and novel chromosomal translocation involving five chromosomes, t(4;12;7;9;22).

background: solid tumors may occur in 3% of the patients with chronic myeloid leukemia (cml). in this paper, we presented a case of cml following treatment of colon cancer. case presentation: a 25 year old man was diagnosed of adenocarcinoma of rectosigmoid treated with fluorouracil-based chemotherapy. following relapse, he received florouracil, oxaliplatin and irinotecan during the next year. ...

Chronic myelogenous leukemia (CML) is a hematopoietic malignancy characterized by an indolent chronic phase that invariably leads to a "blast crisis" indistinguishable from acute leukemia. Using a sensitive assay based on gene transfer and tumorigenesis, we sought evidence that damage to protooncogenes might figure in the progression from the chronic to the blast phase of CML. Seven of the 12 p...